The risk of thrombosis after the second dose of AstraZeneca coronavirus vaccine does not increase, according to a new study from the pharmaceutical company.
The study, published in the journal Lancet, reports that for every one million people who received the first dose of the vaccine, there were 8,1 reports of low platelet thrombosis, known as Thrombocytopenia Syndrome.
The study looked at 49,23 million vaccinations in the EU and the UK by the end of April.
For every million of the 5,62 million second-dose cases that were also studied, there were 2,3 cases of thrombosis.
AstraZeneca executive vice president Mene Pangalos said that "unless Thrombocytopenia Syndrome has been identified after the first dose, these results support the administration of the second dose as appropriate."
The company also said that there are no specific risk factors or specific cause for the thrombosis associated with the drug and that studies are ongoing.
An easyJet flight changed course and made an emergency landing in Heraklion due to…
The evidence presented in the court in which 31-year-old Christopher Gregor is being tried is chilling,...
Freedom of the Press is tested all over the planet by illiberal - totalitarian regimes but…
A 25-year-old man from Nicosia was arrested in Larnaca for illegal possession and...
KEPA, in collaboration with the two major sponsors, NEVISO Skirodema and GIOVANI HOMES, having...
"The Personal Envoy of the Secretary General for Cyprus, Maria Angela Holgin, will hold the...